Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 18Unknown 4Terminated 4Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 10Myeloid 9Lymphoid 9Plasma cell 2Classical hematology 2Breast 2Sarcoma 1Other solid neoplasm 1CNS 1

Conditions

Breast Neoplasms 2

Interventions

Paclitaxel 83Fulvestrant 65Trastuzumab 62Letrozole 61pembrolizumab 53Carboplatin 51Cyclophosphamide 48pertuzumab 46palbociclib 44Anastrozole 41Capecitabine 33Tamoxifen 30Magnetic Resonance Spectroscopy 29exemestane 28Radiotherapy 28Doxorubicin 28ribociclib 26olaparib 26Docetaxel 26Specimen Handling 25abemaciclib 24130-nm albumin-bound paclitaxel 20trastuzumab deruxtecan 19Taxes 19Gemcitabine 19durvalumab 18Surveys and Questionnaires 18Epirubicin 18eribulin 17Alpelisib 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Thiotepa × Breast × Clear all
NCT01057069 2022-10-12

neo-TN

The Netherlands Cancer Institute

Phase 2/3 Active not recruiting
310 enrolled
Breast

Breast Neoplasms

NCT01646034 2022-10-12

Oligo

The Netherlands Cancer Institute

Phase 3 Active not recruiting
74 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡